180 related articles for article (PubMed ID: 38396351)
1. Small Molecule-Drug Conjugates: Opportunities for the Development of Targeted Anticancer Drugs.
Zhang J; Hu F; Aras O; Chai Y; An F
ChemMedChem; 2024 Jun; 19(11):e202300720. PubMed ID: 38396351
[TBL] [Abstract][Full Text] [Related]
2. Advancements in folate receptor targeting for anti-cancer therapy: A small molecule-drug conjugate approach.
Rana A; Bhatnagar S
Bioorg Chem; 2021 Jul; 112():104946. PubMed ID: 33989916
[TBL] [Abstract][Full Text] [Related]
3. Small molecule- and peptide-drug conjugates addressing integrins: A story of targeted cancer treatment.
Paulus J; Sewald N
J Pept Sci; 2024 Jul; 30(7):e3561. PubMed ID: 38382900
[TBL] [Abstract][Full Text] [Related]
4. Small Molecule-Drug Conjugates Emerge as a New Promising Approach for Cancer Treatment.
Wang T; Li M; Wei R; Wang X; Lin Z; Chen J; Wu X
Mol Pharm; 2024 Mar; 21(3):1038-1055. PubMed ID: 38344996
[TBL] [Abstract][Full Text] [Related]
5. Chemical generation of small molecule-based bispecific antibody-drug conjugates for broadening the target scope.
Yamaguchi A; Anami Y; Ha SYY; Roeder TJ; Xiong W; Lee J; Ueno NT; Zhang N; An Z; Tsuchikama K
Bioorg Med Chem; 2021 Feb; 32():116013. PubMed ID: 33482584
[TBL] [Abstract][Full Text] [Related]
6. Advances in non-radioactive PSMA-targeted small molecule-drug conjugates in the treatment of prostate cancer.
Chen M; Cai L; Xiang Y; Zhong L; Shi J
Bioorg Chem; 2023 Dec; 141():106889. PubMed ID: 37813074
[TBL] [Abstract][Full Text] [Related]
7. Small molecule-drug conjugates: A novel strategy for cancer-targeted treatment.
Zhuang C; Guan X; Ma H; Cong H; Zhang W; Miao Z
Eur J Med Chem; 2019 Feb; 163():883-895. PubMed ID: 30580240
[TBL] [Abstract][Full Text] [Related]
8. Enhancing the Safety and Efficacy of PSMA-Based Small-Molecule Drug Conjugates by Linker Stabilization and Conjugation to Transthyretin Binding Ligand.
Amin TU; Emara R; Pal A; Aldawod H; Jiang G; Liang D; Haque Tuhin MT; Balgoname A; Patel AD; Alhamadsheh MM
J Med Chem; 2022 Nov; 65(22):15473-15486. PubMed ID: 36327103
[TBL] [Abstract][Full Text] [Related]
9. Preparation of Ligand-Targeted Drug Conjugates for Cancer Therapy and Their Evaluation In Vitro.
Krishnan MA; Sengupta S; Chelvam V
Curr Protoc Chem Biol; 2018 Dec; 10(4):e50. PubMed ID: 30212603
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil elastase as a versatile cleavage enzyme for activation of αvβ3 integrin-targeted small molecule drug conjugates with different payload classes in the tumor microenvironment.
Rebstock AS; Wiedmann M; Stelte-Ludwig B; Wong H; Johnson AJ; Izumi R; Hamdy A; Lerchen HG
Front Pharmacol; 2024; 15():1358393. PubMed ID: 38495100
[No Abstract] [Full Text] [Related]
11. Tumor Targeting with Small Molecule-Drug Conjugates (SMDCs) - Can They be Better than ADCs?
Altmann KH
Chimia (Aarau); 2018 Mar; 72(3):154-155. PubMed ID: 29631670
[No Abstract] [Full Text] [Related]
12. A branched small molecule-drug conjugate nanomedicine strategy for the targeted HCC chemotherapy.
Li SS; Zhang CM; Wu JD; Liu C; Liu ZP
Eur J Med Chem; 2022 Jan; 228():114037. PubMed ID: 34883290
[TBL] [Abstract][Full Text] [Related]
13. Small-molecule PROTACs: novel agents for cancer therapy.
Wan Y; Yan C; Gao H; Liu T
Future Med Chem; 2020 May; 12(10):915-938. PubMed ID: 32270707
[TBL] [Abstract][Full Text] [Related]
14. In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment.
Bocci M; Zana A; Principi L; Lucaroni L; Prati L; Gilardoni E; Neri D; Cazzamalli S; Galbiati A
J Control Release; 2024 Mar; 367():779-790. PubMed ID: 38346501
[TBL] [Abstract][Full Text] [Related]
15. Optimizing the enzymatic release of MMAE from
Zambra M; Ranđelović I; Talarico F; Borbély A; Svajda L; Tóvári J; Mező G; Bodero L; Colombo S; Arrigoni F; Fasola E; Gazzola S; Piarulli U
Front Pharmacol; 2023; 14():1215694. PubMed ID: 37492088
[TBL] [Abstract][Full Text] [Related]
16. Development of small molecule-drug conjugates based on derivatives of natural proteasome inhibitors that exhibit selectivity for PSMA-expressing cancer cells.
Obara T; Kawano N; Tatsumi K; Katsuyama A; Nakajima K; Ogawa M; Ichikawa S
Bioorg Med Chem; 2024 Jun; 108():117773. PubMed ID: 38850999
[TBL] [Abstract][Full Text] [Related]
17. Antibody-Drug Conjugates-A Tutorial Review.
Baah S; Laws M; Rahman KM
Molecules; 2021 May; 26(10):. PubMed ID: 34063364
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers.
Dal Corso A; Caruso M; Belvisi L; Arosio D; Piarulli U; Albanese C; Gasparri F; Marsiglio A; Sola F; Troiani S; Valsasina B; Pignataro L; Donati D; Gennari C
Chemistry; 2015 Apr; 21(18):6921-9. PubMed ID: 25784522
[TBL] [Abstract][Full Text] [Related]
19. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
[TBL] [Abstract][Full Text] [Related]
20. Development of Antibody-Drug Conjugates: Future Perspective Towards Solid Tumor Treatment.
Pramanik D
Anticancer Agents Med Chem; 2023; 23(6):642-657. PubMed ID: 36321237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
